106 related articles for article (PubMed ID: 18372020)
1. Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups.
Chen CH; Tzai TS; Huang SP; Wu HC; Tai HC; Chang YH; Pu YS
Urology; 2008 Dec; 72(6):1287-92. PubMed ID: 18372020
[TBL] [Abstract][Full Text] [Related]
2. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England.
Jack RH; Davies EA; Møller H
BJU Int; 2010 May; 105(9):1226-30. PubMed ID: 19878505
[TBL] [Abstract][Full Text] [Related]
4. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
5. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
7. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
8. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
[TBL] [Abstract][Full Text] [Related]
10. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
[TBL] [Abstract][Full Text] [Related]
11. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
[TBL] [Abstract][Full Text] [Related]
12. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
14. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.
Fleischmann A; Schobinger S; Schumacher M; Thalmann GN; Studer UE
Prostate; 2009 Mar; 69(4):352-62. PubMed ID: 19016478
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
16. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
Wiebe E; Rodrigues G; Lock M; D'Souza D; Stitt L
Can J Urol; 2008 Jun; 15(3):4078-83. PubMed ID: 18570713
[TBL] [Abstract][Full Text] [Related]
17. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
Ryan CJ; Elkin EP; Cowan J; Carroll PR
Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
19. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
[TBL] [Abstract][Full Text] [Related]
20. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]